FDA Removes Age Restriction for neffy® 1 mg, Expanding Pediatric Market for ARS Pharma
summarizeSummary
The FDA has approved an update to the neffy® 1 mg (epinephrine nasal spray) label, removing the age requirement. This allows all children weighing 33 lbs. or more to use the product, eliminating the previous restriction that required pediatric patients to be at least four years of age. This significantly expands the addressable market for ARS Pharmaceuticals' key product, Neffy, which was highlighted in the recent 10-K as a driver of product revenue growth. The company estimates that approximately one-quarter of patients requiring epinephrine are children within the 33-66 lbs. weight range, including about 25% under the age of four, representing a substantial new market segment. This label expansion is a material positive catalyst, potentially boosting sales and market penetration by addressing caregiver concerns about needle-based treatments for younger children. Investors will now monitor the commercial uptake of Neffy in this newly accessible pediatric demographic.
At the time of this announcement, SPRY was trading at $8.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $850M. The 52-week trading range was $6.66 to $18.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.